Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility
Mauricette Michallet(Université Claude Bernard Lyon 1), Xavier Thomas(Hôpital Lyon Sud), Adriana Pleșa(Hospices Civils de Lyon), Mohamed Elhamri(Hôpital Edouard Herriot), Jérémy Monfray(Hôpital Lyon Sud), Valérie Dubois(Établissement Français du Sang), Fiorenza Barraco(Hôpital Lyon Sud), Laure Lebras(Centre Léon Bérard), Isabelle Tigaud(Inserm), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Mohamad Sobh(Ottawa Hospital), Franck E. Nicolini(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud), Sandrine Hayette(Hôpital Claude Huriez), Lila Gilis(Hospices Civils de Lyon)
Cited by 1
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547